TandemAI, an AI-driven drug discovery company integrating physics-based computation with wet lab capabilities, announced the securing of $22 million in additional funding to accelerate platform development. The round included participation from new and existing investors, bringing total capital raised since October 2021 to more than $80 million.
TandemAI operates a fully integrated discovery engine supported by a team of over 300 professionals. The platform has generated more than ten differentiated candidates advancing toward clinical development. Collaborations now include four of the world’s top ten multinational pharmaceutical companies, along with a global network exceeding 150 partners and clients.
“TandemAI has successfully executed on its approach to build and commercialize a powerful drug discovery platform by integrating AI and physics-based computational technologies with wet lab techniques,” said Peter Zhao, Managing Director at V-Capital. “With this funding, the company and its outstanding team are well positioned to grow its existing small molecule business and, with the recent merger with Perpetual Medicines, capitalize on the significant emerging opportunities in peptide and antibody-peptide conjugate discovery.”
KHK Fund stated, “AI and advanced physics-based methods are now essential for drug discovery. TandemAI’s platform has notably enhanced R&D efficiency and success rates in small molecule and peptide drug discovery, driving rapid growth even during the pharmaceutical market downturn. We are pleased to support the company’s continued growth.”
“The financing is a strong vote of confidence in our progress to date and in our strategy,” said Jeff He, co-founder and CEO of TandemAI. “This funding will support AI and computational physics-based model development for multiple modalities, as well as wet lab capacity expansion to accommodate our rapidly growing client base.” Mr. He highlighted that the merger with Perpetual Medicines added seasoned drug developers Kerry Blanchard, MD, PhD, and Ved Srivastava, PhD, strengthening TandemAI’s end-to-end discovery and development capabilities.